Mereo BioPharma
Setrusumab ready to advance into pivotal studiesMereo BioPharma
Setrusumab set to advanceMereo BioPharma
Entering an important 12 month periodMereo BioPharma
Accelerated approval path for NAVIMereo BioPharma
Encouraging interim BPS-804 data in OIMereo BioPharma
Focus shifts back to imminent dataMereo BioPharma
Path cleared for partnering of acumapimod (BCT-197)Mereo BioPharma
Executing a well articulated strategyMereo BioPharma
Merger with NASDAQ-listed OncoMedMereo BioPharma
Phase II starts with backing from patient support group